Literature DB >> 10984673

Neurotransmitter changes in the pathophysiology of Lesch-Nyhan syndrome.

Y Saito1, S Takashima.   

Abstract

The neurological symptoms of Lesch-Nyhan syndrome (LNS) are assumed to result from the neurotransmitter changes in this disorder. Among them, the dopaminergic system is believed to play a role in the self-injurious behavior through receptor supersensitivity. However, the precise mechanism underlying the dopamine supersensitivity remains unclear. An increased serotonergic action in the striatum may be crucial for the appearance of self-injurious behavior, and pharmacological evidence suggests the efficacy of serotonin agonists/antagonists for the treatment of the self-mutilation in LNS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984673     DOI: 10.1016/s0387-7604(00)00143-1

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  21 in total

1.  Adenosine, dopamine and serotonin receptors imbalance in lymphocytes of Lesch-Nyhan patients.

Authors:  Marta G García; Juan G Puig; Rosa J Torres
Journal:  J Inherit Metab Dis       Date:  2012-03-09       Impact factor: 4.982

2.  Regional brain volume abnormalities in Lesch-Nyhan disease and its variants: a cross-sectional study.

Authors:  David J Schretlen; Mark Varvaris; Tiffany E Ho; Tracy D Vannorsdall; Barry Gordon; James C Harris; H A Jinnah
Journal:  Lancet Neurol       Date:  2013-12       Impact factor: 44.182

3.  Altered gastrointestinal motility in an animal model of Lesch-Nyhan disease.

Authors:  Maria G Zizzo; Monica Frinchi; Domenico Nuzzo; Hyder A Jinnah; Giuseppa Mudò; Daniele F Condorelli; Francesco Caciagli; Renata Ciccarelli; Patrizia Di Iorio; Flavia Mulè; Natale Belluardo; Rosa Serio
Journal:  Auton Neurosci       Date:  2017-12-20       Impact factor: 3.145

Review 4.  Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.

Authors:  Noha F Minshawi; Sarah Hurwitz; Danielle Morriss; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2015-06

5.  Deficiency of the purine metabolic gene HPRT dysregulates microRNA-17 family cluster and guanine-based cellular functions: a role for EPAC in Lesch-Nyhan syndrome.

Authors:  Ghiabe-Henri Guibinga; Fiona Murray; Nikki Barron; William Pandori; Gorjan Hrustanovic
Journal:  Hum Mol Genet       Date:  2013-06-25       Impact factor: 6.150

6.  Basal ganglia dopamine loss due to defect in purine recycling.

Authors:  Kiyoshi Egami; Silaja Yitta; Suhail Kasim; J Chris Lewers; Rosalinda C Roberts; Mohamed Lehar; H A Jinnah
Journal:  Neurobiol Dis       Date:  2007-02-08       Impact factor: 5.996

7.  Consequences of impaired purine recycling on the proteome in a cellular model of Lesch-Nyhan disease.

Authors:  Eric B Dammer; Martin Göttle; Duc M Duong; John Hanfelt; Nicholas T Seyfried; H A Jinnah
Journal:  Mol Genet Metab       Date:  2015-03-05       Impact factor: 4.797

8.  A model of behavioral treatments for self-mutilation behavior in Lesch-Nyhan syndrome.

Authors:  Eric A Zilli; Michael E Hasselmo
Journal:  Neuroreport       Date:  2008-03-05       Impact factor: 1.837

Review 9.  Delineation of the motor disorder of Lesch-Nyhan disease.

Authors:  H A Jinnah; Jasper E Visser; James C Harris; Alfonso Verdu; Laura Larovere; Irene Ceballos-Picot; Pedro Gonzalez-Alegre; Vladimir Neychev; Rosa J Torres; Olivier Dulac; Isabelle Desguerre; David J Schretlen; Kenneth L Robey; Gabor Barabas; Bastiaan R Bloem; William Nyhan; Raquel De Kremer; Gary E Eddey; Juan G Puig; Stephen G Reich
Journal:  Brain       Date:  2006-03-20       Impact factor: 13.501

10.  Effect of hypoxanthine, antioxidants and allopurinol on cholinesterase activities in rats.

Authors:  Morgahna Nathalie Wamser; Eduardo Fernandes Leite; Vinícius Vialle Ferreira; Daniela Delwing-de Lima; José Geraldo Pereira da Cruz; Angela T S Wyse; Débora Delwing-Dal Magro
Journal:  J Neural Transm (Vienna)       Date:  2013-02-12       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.